Abstract
Serum lipid abnormalities (dyslipidemias) are major risk factors for cardiovascular disease in type 2 diabetes mellitus. Recent findings provide new evidence that dyslipidemia characterized by elevated triglycerides and non-high-density lipoprotein cholesterol levels with a decreased high-density lipoprotein cholesterol level are risk factors for cardiovascular disease in patients with type 2 diabetes. There are multiple therapeutic agents to help patients to achieve target lipid levels, but understanding the molecular mechanisms could provide useful information for new treatment strategies for diabetic dyslipidemia.